obtained a license to develop and commercialize Dyax
’ compound DX-88
in retinal diseases. The agreement gives Fovea marketing rights in the EU, while Dyax retains marketing rights for all other territories. If commercialized, each company will pay the other a tiered royalty on net sales in their respective territories.
Fovea will fund development of DX-88 for the treatment of RVO-induced macular edema (retinal vein occlusion) for approval in worldwide markets. For all other ophthalmic uses of DX-88, Fovea will be responsible for development to meet EU regulatory requirements and Dyax will take care of any additional requirements needed to obtain approval outside the EU.
“As a potent plasma kallikrein inhibitor, DX-88 has the potential to be a breakthrough therapy in reducing macular edema, a leading cause of visual loss in multiple ophthalmic diseases,” explains Bernard Gilly, president and CEO of Fovea.
To comment on this story, go to BLOGbiotech.